Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe study record for the nivolumab and ipilimumab prostate cancer trial is now displayed, including its treatment plan, eligibility criteria, locations, and outcome measures.SummaryDifference47%

- Check16 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434. It appears above the ClinicalTrials.gov error message.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe ClinicalTrials.gov footer revision advanced from v3.7.0 to v3.7.1, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedAdded a new Revision: v3.7.0 tag and removed a broad list of metadata terms and keywords. This updates how the record is indexed and what topics are associated with it, without changing core study content.SummaryDifference18%

Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.